Advanced kidney cancer traditionally carries a poor prognosis, with most patients experiencing disease progression despite multiple treatment attempts. This exceptional outcome demonstrates the transformative potential of immunotherapy in achieving durable cancer eradication, even after conventional targeted therapies have failed.
A 51-year-old patient with metastatic clear cell renal carcinoma achieved complete disease elimination following treatment with nivolumab, a PD-1 checkpoint inhibitor. After initial tumor removal and failure of two targeted therapies (sunitinib and axitinib), nivolumab was administered as third-line treatment in 2018. The patient has maintained complete remission for nearly five years, with no detectable cancer since October 2020 and no ongoing treatment for the past 27 months. Manageable immune-related side effects including kidney and colon inflammation were successfully controlled with corticosteroids.
This case represents the upper tier of immunotherapy success in renal cell carcinoma, where complete responses occur in only 5-10% of patients. While single case reports cannot establish treatment efficacy, this outcome aligns with emerging evidence that checkpoint inhibitors can occasionally produce extraordinarily durable responses in kidney cancer. The sustained remission without ongoing therapy suggests potential immune memory against cancer antigens. However, long-term follow-up remains critical, as late relapses can occur even after years of apparent cure. This case reinforces the paradigm shift toward immunotherapy in advanced renal cancer while highlighting the unpredictable nature of individual treatment responses.